A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Atopic dermatitis; Eczema; Pruritus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
    • 15 Feb 2017 According to a Vanda Pharmaceuticals media release, enrollment in the study is approaching completion and results are expected in mid 2017.
    • 27 Jul 2016 According to a Vanda Pharmaceuticals media release, results from this trial are expected in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top